Patents Examined by Sean E Aeder
-
Patent number: 11969462Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.Type: GrantFiled: June 21, 2018Date of Patent: April 30, 2024Assignee: TransgeneInventors: Kaïdre Bendjama, Nathalie Silvestre, Jean-Baptiste Marchand, Benoît Grellier
-
Patent number: 11965028Abstract: Disclosed are NRP-1 peptides vaccines corresponding to epitopes associated to diseases and capable of triggering the immune response such as production of anti-NRP-1 antibodies with specificity to GAG-modified NRP-1 that are able to block DNA damages response (DDR). In particular, NRP-1 peptides vaccines and their derived anti-NRP-1 antibodies (NRP-1 peptides antibodies) specific for an epitope located in the binding domain of leptin on NRP-1 that are able to enter into the nucleus and to block DNA damages response (DDR) and having properties of interest in the treatment of diseases involving NRP-1/OBR complex. The NRP-1 peptide vaccines and the NRP-1 peptides antibodies are of interest in therapies; especially in diseases related to DNA damage response and Glycosaminoglycans.Type: GrantFiled: June 23, 2023Date of Patent: April 23, 2024Assignee: TheranovirInventors: Zakia Belaid-Sandal, Elie Matta, Flavien Berthou
-
Patent number: 11952429Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: GrantFiled: June 24, 2022Date of Patent: April 9, 2024Inventors: J. Andrew Bristol, Judith A. Kantor
-
Patent number: 11945880Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: December 3, 2021Date of Patent: April 2, 2024Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 11939637Abstract: In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.Type: GrantFiled: February 19, 2021Date of Patent: March 26, 2024Assignees: Massachusetts Institute of Technology, The General Hospital CorporationInventors: Nir Hacohen, Michael S. Rooney
-
Patent number: 11932704Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.Type: GrantFiled: October 29, 2021Date of Patent: March 19, 2024Assignee: SANOFIInventors: Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
-
Patent number: 11919957Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: GrantFiled: October 17, 2022Date of Patent: March 5, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, William J. Geese, Sabine Maier, Giovanni Selvaggi, Joseph Daniel Szustakowski
-
Patent number: 11921115Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer. In some embodiments, the disclosure provides improved prostate antigen standards for quantifying levels of prostate antigens.Type: GrantFiled: March 25, 2016Date of Patent: March 5, 2024Assignee: OPKO Diagnostics, LLCInventors: Vincent Linder, Christina Higgins, Kim Pettersson
-
Patent number: 11918648Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.Type: GrantFiled: August 21, 2020Date of Patent: March 5, 2024Assignees: MERCK SHARP & DOHME LLC, TRISALUS LIFE SCIENCES, INC.Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
-
Patent number: 11897954Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.Type: GrantFiled: November 15, 2021Date of Patent: February 13, 2024Assignees: Astellas Pharma Inc., National Cancer CenterInventors: Yoshiyuki Tenda, Masatoshi Yuri, Daisuke Yamajuku, Takeshi Tsutsumi, Yuko Kusuzaki, Hiroki Sasaki, Fumiko Chiwaki, Masayuki Komatsu
-
Patent number: 11897959Abstract: An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.Type: GrantFiled: September 3, 2021Date of Patent: February 13, 2024Assignee: BIOATLA, INC.Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 11892453Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: June 4, 2021Date of Patent: February 6, 2024Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet
-
Patent number: 11879005Abstract: This invention relates to novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.Type: GrantFiled: January 29, 2022Date of Patent: January 23, 2024Assignee: Numab Therapeutics AGInventors: Sebastian Meyer, David Urech
-
Patent number: 11874277Abstract: Methods are provided for assessing risk of developing esophageal adenocarcinoma in a subject using one or more of the following marker genes/proteins: ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. Methods are also provided for determining expression of one or more esophageal adenocarcinoma risk factors in a subject. Methods are also provided for treating esophageal adenocarcinoma in a subject, for preventing esophageal adenocarcinoma in a subject, for inhibiting or decreasing proliferation of esophageal adenocarcinoma cells, for inhibiting or decreasing migration of esophageal adenocarcinoma cells, or for increasing susceptibility to cytotoxicity or inducing cell death of esophageal adenocarcinoma cells.Type: GrantFiled: May 19, 2021Date of Patent: January 16, 2024Assignee: PROPHASE LABS, INC.Inventors: Joe Abdo, Sumeet K. Mittal, Devendra K. Agrawal
-
Patent number: 11867688Abstract: The present invention relates provides methods of predicting cell sensitivity to a test agent. In some embodiments, the cells are cultured in a culture medium having serum.Type: GrantFiled: July 27, 2020Date of Patent: January 9, 2024Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Anthony Letai, Patrick Bhola, Jeremy Ryan
-
Patent number: 11859011Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: October 18, 2021Date of Patent: January 2, 2024Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 11851492Abstract: A method is used for treating bone metastasis diseases in subjects. The method preferably depends on whether the subject shows certain specific proteins levels in one or more body fluids prior to or during treatment. The treatment includes the administration of at least one pan ?v integrin inhibitor to a subject, a medicament for use in said new methods, and a method of predicting the outcome of a treatment with at least one pan ?v integrin inhibitor based on the specific protein levels in one or more body fluids of the subject.Type: GrantFiled: March 14, 2022Date of Patent: December 26, 2023Assignee: Merck Patent GmbHInventors: Josef Straub, Eike Staub
-
Patent number: 11845994Abstract: Recent large-scale analyses have demonstrated that the genomic landscape of human cancer is complex and variable among individuals of the same tumor type. Such underlying genetic differences may in part be responsible for the varying therapeutic responses observed in cancer patients. To examine the effect of somatic genetic changes in colorectal cancer on sensitivity to a common targeted therapy, we performed complete exome sequence and copy number analyses of 129 tumors that were KRAS wild-type and analyzed their response to anti-EGFR antibody blockade in patient-derived tumorgraft models. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade.Type: GrantFiled: April 8, 2021Date of Patent: December 19, 2023Assignees: The Johns Hopkins University, University of TorinoInventors: Victor E. Velculescu, Eniko Papp, Vilmos Adleff, Andrea Bertotti, Livio Trusolino
-
Patent number: 11839655Abstract: A method and combination for treating a cancer patient by combining two distinct immuno-therapy solutions for administration to a patient within a common time period, comprising a checkpoint inhibitor antibody component such as a PD-1 or PD-L1 antibody administered by infusion, and a TAA/ecdCD40L vaccine component administered subcutaneously, wherein an initial antibody component administered is followed by at least several successive antibody boosts and an initial vaccine component administered is followed by at least several successive vaccine boosts, both the initial and boosts of each administered within at least said common time period, wherein the combined administration of said two distinct immuno-therapy solutions provides for an enhanced therapeutic effect, over that of the therapeutic effect of either of the two distinct immuno-therapy component solutions when administered alone as monotherapy.Type: GrantFiled: January 29, 2018Date of Patent: December 12, 2023Assignee: MicroVAX, LLCInventors: Albert B. Deisseroth, Nagy Habib
-
Patent number: 11840740Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: GrantFiled: June 21, 2021Date of Patent: December 12, 2023Assignee: INBIOMOTION S.L.Inventors: Roger Gomis, Joël Jean-Mairet